What is Zacks Research's Estimate for MMSI FY2028 Earnings?

Key Points

• Zacks Research raised its FY2028 EPS estimate for Merit Medical to $4.10 (from $4.09), compared with the current consensus full-year estimate of $3.62 per share.
• In its most recent quarter Merit beat expectations with EPS of $1.04 (vs. $0.96 est.) and revenue of $393.94M (up 10.9% YoY), and the company has set FY2026 guidance of $4.01–$4.15 EPS.
• Shares trade well below analyst price targets: the stock has a market cap of about $4.02B, an average analyst rating of "Moderate Buy" with a consensus price target of $99.56, and institutional investors own roughly 99.66% of the shares.

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Zacks Research lifted their FY2028 earnings per share estimates for shares of Merit Medical Systems in a research report issued on Monday, April 27th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $4.10 per share for the year, up from their prior estimate of $4.09. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.62 per share.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.08. The business had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.Merit Medical Systems's revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.93 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS.

Other equities research analysts have also issued reports about the company. Barrington Research decreased their price target on Merit Medical Systems from $109.00 to $107.00 and set an "outperform" rating on the stock in a research report on Monday, April 20th. Needham & Company LLC restated a "buy" rating and set a $101.00 price target on shares of Merit Medical Systems in a research report on Wednesday, April 1st. Weiss Ratings restated a "hold (c)" rating on shares of Merit Medical Systems in a research report on Friday, March 27th. Canaccord Genuity Group decreased their price target on Merit Medical Systems from $99.00 to $90.00 and set a "buy" rating on the stock in a research report on Tuesday, April 7th. Finally, Compass Point set a $107.00 price target on Merit Medical Systems in a research report on Monday, April 20th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $99.56.

Merit Medical Systems Stock Down 1.7%

NASDAQ MMSI opened at $67.43 on Tuesday. The firm has a market cap of $4.02 billion, a PE ratio of 31.81, a price-to-earnings-growth ratio of 1.93 and a beta of 0.64. Merit Medical Systems has a one year low of $66.34 and a one year high of $100.19. The stock's 50 day simple moving average is $71.61 and its 200 day simple moving average is $80.05. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.34 and a quick ratio of 2.95.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd bought a new position in shares of Merit Medical Systems in the 1st quarter worth $2,919,000. Elevation Point Wealth Partners LLC bought a new position in Merit Medical Systems during the first quarter worth about $353,000. Boston Trust Walden Corp bought a new position in Merit Medical Systems during the first quarter worth about $19,108,000. Conestoga Capital Advisors LLC lifted its holdings in Merit Medical Systems by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier's stock worth $149,407,000 after acquiring an additional 81,030 shares in the last quarter. Finally, Palouse Capital Management Inc. lifted its holdings in Merit Medical Systems by 29.8% during the first quarter. Palouse Capital Management Inc. now owns 1,315 shares of the medical instruments supplier's stock worth $91,000 after acquiring an additional 302 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.